Company: LIMN
Filing Date: 2025-06-24
Form Type: S-1
Source: 0001410578-25-001432
Chunk: 212

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-24
Form: S-1
Chunk 212
---
 ​ 
 For the three months ended March 31, 2025 | ​ | ​      |     ​ | ​ |                     ​ | ​ | ​      |   ​ | ​ | ​                  |     ​ | ​ | ​           |       ​ | ​ | ​              |       ​ |
|:--------------------------------------|:--|------------------------------------------:|:--|:-------|------:|:--|----------------------:|:--|:-------|----:|:--|:-------------------|------:|:--|:------------|--------:|:--|:---------------|--------:|
| ​                                     | ​ |                                         ​ |   |        |       | ​ |                     ​ |   |        |     | ​ | ​                  |       | ​ | ​           |         | ​ | ​              |         |
| ​                                     | ​ |                      Class A Member Units |   |        |       | ​ | Class B Members Units |   |        |     | ​ | Additional Paid-in |       | ​ | Accumulated |         | ​ | Total Members’ |         |
| ​                                     |   |                                     Units |   | Amount |       |   |                 Units |   | Amount |     |   | Capital            |       |   | Deficit     |         |   | Deficit        |         |
| Balance at December 31, 2024          |   |                                95,555,554 | ​ | $      | 4,547 |   |            16,666,666 | ​ | $      | 167 | ​ | $                  | 4,611 | ​ | $           | -28,665 | ​ | $              | -19,340 |
| Net loss                              |   |                                         — | ​ |        |     — |   |                     — | ​ |        |   — | ​ |                    |     — | ​ |             |    -328 | ​ |                |    -328 |
| Balance at March 31, 2025 (unaudited) |   |                                95,555,554 | ​ | $      | 4,547 |   |            16,666,666 | ​ | $      | 167 | ​ | $                  | 4,611 | ​ | $           | -28,993 | ​ | $              | -19,668 |

The accompanying notes are an integral part of these unaudited condensed financial statements.

F-21

L